- Home
- EML vs ABOS Comparison
EML vs ABOS Comparison
Compare EML & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- ABOS
- Stock Information
- Founded
- EML 1858
- ABOS 1996
- Country
- EML United States
- ABOS United States
- Employees
- EML N/A
- ABOS N/A
- Industry
- EML Industrial Machinery/Components
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- EML Consumer Discretionary
- ABOS Health Care
- Exchange
- EML Nasdaq
- ABOS Nasdaq
- Market Cap
- EML 191.3M
- ABOS 99.1M
- IPO Year
- EML N/A
- ABOS 2021
- Fundamental
- Price
- EML $26.66
- ABOS $1.56
- Analyst Decision
- EML
- ABOS Strong Buy
- Analyst Count
- EML 0
- ABOS 3
- Target Price
- EML N/A
- ABOS $9.33
- AVG Volume (30 Days)
- EML 11.4K
- ABOS 379.4K
- Earning Date
- EML 11-01-2024
- ABOS 11-12-2024
- Dividend Yield
- EML 1.66%
- ABOS N/A
- EPS Growth
- EML N/A
- ABOS N/A
- EPS
- EML N/A
- ABOS N/A
- Revenue
- EML $284,461,286.00
- ABOS N/A
- Revenue This Year
- EML N/A
- ABOS N/A
- Revenue Next Year
- EML N/A
- ABOS N/A
- P/E Ratio
- EML $13.23
- ABOS N/A
- Revenue Growth
- EML 7.70
- ABOS N/A
- 52 Week Low
- EML $22.63
- ABOS $1.54
- 52 Week High
- EML $35.78
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- EML 43.93
- ABOS 30.29
- Support Level
- EML $25.31
- ABOS $1.69
- Resistance Level
- EML $26.90
- ABOS $1.88
- Average True Range (ATR)
- EML 0.69
- ABOS 0.13
- MACD
- EML 0.00
- ABOS -0.00
- Stochastic Oscillator
- EML 54.66
- ABOS 4.88
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.